417 related articles for article (PubMed ID: 17981736)
1. The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism.
Beldi G; Enjyoji K; Wu Y; Miller L; Banz Y; Sun X; Robson SC
Front Biosci; 2008 Jan; 13():2588-603. PubMed ID: 17981736
[TBL] [Abstract][Full Text] [Related]
2. Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: Potential as therapeutic targets.
Atkinson B; Dwyer K; Enjyoji K; Robson SC
Blood Cells Mol Dis; 2006; 36(2):217-22. PubMed ID: 16476557
[TBL] [Abstract][Full Text] [Related]
3. Purinergic signaling in liver disease.
Vaughn BP; Robson SC; Longhi MS
Dig Dis; 2014; 32(5):516-24. PubMed ID: 25034284
[TBL] [Abstract][Full Text] [Related]
4. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation.
Robson SC; Wu Y; Sun X; Knosalla C; Dwyer K; Enjyoji K
Semin Thromb Hemost; 2005 Apr; 31(2):217-33. PubMed ID: 15852225
[TBL] [Abstract][Full Text] [Related]
5. Pathological roles of purinergic signaling in the liver.
Vaughn BP; Robson SC; Burnstock G
J Hepatol; 2012 Oct; 57(4):916-20. PubMed ID: 22709619
[TBL] [Abstract][Full Text] [Related]
6. Regulated catalysis of extracellular nucleotides by vascular CD39/ENTPD1 is required for liver regeneration.
Beldi G; Wu Y; Sun X; Imai M; Enjyoji K; Csizmadia E; Candinas D; Erb L; Robson SC
Gastroenterology; 2008 Nov; 135(5):1751-60. PubMed ID: 18804472
[TBL] [Abstract][Full Text] [Related]
7. Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis.
Beldi G; Wu Y; Banz Y; Nowak M; Miller L; Enjyoji K; Haschemi A; Yegutkin GG; Candinas D; Exley M; Robson SC
Hepatology; 2008 Sep; 48(3):841-52. PubMed ID: 18752325
[TBL] [Abstract][Full Text] [Related]
8. Deletion of cd39/entpd1 results in hepatic insulin resistance.
Enjyoji K; Kotani K; Thukral C; Blumel B; Sun X; Wu Y; Imai M; Friedman D; Csizmadia E; Bleibel W; Kahn BB; Robson SC
Diabetes; 2008 Sep; 57(9):2311-20. PubMed ID: 18567823
[TBL] [Abstract][Full Text] [Related]
9. Purinergic signaling during intestinal inflammation.
Longhi MS; Moss A; Jiang ZG; Robson SC
J Mol Med (Berl); 2017 Sep; 95(9):915-925. PubMed ID: 28547076
[TBL] [Abstract][Full Text] [Related]
10. Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity.
Deaglio S; Robson SC
Adv Pharmacol; 2011; 61():301-32. PubMed ID: 21586363
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury.
Guckelberger O; Sun XF; Sévigny J; Imai M; Kaczmarek E; Enjyoji K; Kruskal JB; Robson SC
Thromb Haemost; 2004 Mar; 91(3):576-86. PubMed ID: 14983235
[TBL] [Abstract][Full Text] [Related]
12. Extracellular ATP signaling and clinical relevance.
Dou L; Chen YF; Cowan PJ; Chen XP
Clin Immunol; 2018 Mar; 188():67-73. PubMed ID: 29274390
[TBL] [Abstract][Full Text] [Related]
13. Development of a novel strategy to target CD39 antithrombotic activity to the endothelial-platelet microenvironment in kidney ischemia-reperfusion injury.
Sashindranath M; Dwyer KM; Dezfouli S; Selan C; Crikis S; Lu B; Yuan Y; Hickey MJ; Peter K; Robson SC; Cowan PJ; Nandurkar HH
Purinergic Signal; 2017 Jun; 13(2):259-265. PubMed ID: 28343356
[TBL] [Abstract][Full Text] [Related]
14. Role of extracellular ATP metabolism in regulation of platelet reactivity.
Birk AV; Broekman MJ; Gladek EM; Robertson HD; Drosopoulos JH; Marcus AJ; Szeto HH
J Lab Clin Med; 2002 Sep; 140(3):166-75. PubMed ID: 12271274
[TBL] [Abstract][Full Text] [Related]
15. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.
Savio LEB; de Andrade Mello P; Figliuolo VR; de Avelar Almeida TF; Santana PT; Oliveira SDS; Silva CLM; Feldbrügge L; Csizmadia E; Minshall RD; Longhi MS; Wu Y; Robson SC; Coutinho-Silva R
J Hepatol; 2017 Oct; 67(4):716-726. PubMed ID: 28554875
[TBL] [Abstract][Full Text] [Related]
16. Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/ENTPD1 null mice.
Sun X; Han L; Seth P; Bian S; Li L; Csizmadia E; Junger WG; Schmelzle M; Usheva A; Tapper EB; Baffy G; Sukhatme VP; Wu Y; Robson SC
Hepatology; 2013 Jan; 57(1):205-16. PubMed ID: 22859060
[TBL] [Abstract][Full Text] [Related]
17. Expression of NTPDase1 and NTPDase2 in murine kidney: relevance to regulation of P2 receptor signaling.
Kishore BK; Isaac J; Fausther M; Tripp SR; Shi H; Gill PS; Braun N; Zimmermann H; Sévigny J; Robson SC
Am J Physiol Renal Physiol; 2005 May; 288(5):F1032-43. PubMed ID: 15632415
[TBL] [Abstract][Full Text] [Related]
18. Characterization of soluble CD39 (SolCD39/NTPDase1) from PiggyBac nonviral system as a tool to control the nucleotides level.
Beckenkamp LR; Iser IC; Onzi GR; Fontoura DMSD; Bertoni APS; Sévigny J; Lenz G; Wink MR
Biochem J; 2019 Jun; 476(11):1637-1651. PubMed ID: 31085558
[TBL] [Abstract][Full Text] [Related]
19. [Purinergic signals].
Lazarowski ER; Schwarzbaum PJ
Medicina (B Aires); 2009; 69(2):267-76. PubMed ID: 19435702
[TBL] [Abstract][Full Text] [Related]
20. Conversion of extracellular ATP into adenosine: a master switch in renal health and disease.
Dwyer KM; Kishore BK; Robson SC
Nat Rev Nephrol; 2020 Sep; 16(9):509-524. PubMed ID: 32641760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
